Bone marrow transplantation for severe aplastic anemia.

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Allogeneic marrow transplantation from HLA-identical siblings is a successful treatment for severe aplastic anemia.
• Survival rates range from 70-80%, influenced by patient age.
• Graft rejection and graft-versus-host disease (GVHD) are primary complications, especially with non-identical or unrelated donors.

Purpose of the Study:

• To review the effectiveness of allogeneic marrow transplantation for severe aplastic anemia.
• To discuss challenges including graft rejection and GVHD.
• To explore current research on immunosuppressive regimens to mitigate complications.

Main Methods:

• Review of existing literature on allogeneic marrow transplantation for severe aplastic anemia.
• Analysis of factors influencing graft rejection and GVHD incidence.
• Evaluation of pre- and post-transplant immunosuppressive strategies.

Main Results:

• Successful hematopoiesis restoration and long-term survival in 70-80% of recipients with HLA-identical sibling transplants.
• Younger patients demonstrate improved survival rates.
• Graft rejection incidence is 10-32% with cyclophosphamide alone, reduced by donor buffy coat cells and radiation but increasing GVHD and secondary malignancies.
• Acute GVHD affects 18-40% of patients, with risk factors including previous pregnancy in female donors and patient age.
• Chronic GVHD occurs in approximately 25% of recipients.

Conclusions:

• HLA-identical sibling marrow transplantation is effective for severe aplastic anemia, particularly in younger patients.
• Graft rejection and GVHD necessitate ongoing research into optimized immunosuppressive protocols.
• Further investigation into non-identical and unrelated donor transplantation is crucial.